X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SUN PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SUN PHARMA AUROBINDO PHARMA/
SUN PHARMA
 
P/E (TTM) x 14.0 25.1 55.7% View Chart
P/BV x 3.6 3.7 97.9% View Chart
Dividend Yield % 0.4 0.6 69.3%  

Financials

 AUROBINDO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
SUN PHARMA
Mar-17
AUROBINDO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs895842 106.3%   
Low Rs622572 108.7%   
Sales per share (Unadj.) Rs254.6131.6 193.4%  
Earnings per share (Unadj.) Rs39.332.7 120.1%  
Cash flow per share (Unadj.) Rs46.638.0 122.7%  
Dividends per share (Unadj.) Rs2.503.50 71.4%  
Dividend yield (eoy) %0.30.5 66.6%  
Book value per share (Unadj.) Rs160.0152.7 104.7%  
Shares outstanding (eoy) m585.882,399.26 24.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.05.4 55.4%   
Avg P/E ratio x19.321.6 89.3%  
P/CF ratio (eoy) x16.318.6 87.4%  
Price / Book Value ratio x4.74.6 102.4%  
Dividend payout %6.410.7 59.5%   
Avg Mkt Cap Rs m444,3901,696,877 26.2%   
No. of employees `00014.017.5 79.8%   
Total wages/salary Rs m17,67849,023 36.1%   
Avg. sales/employee Rs Th10,667.818,028.3 59.2%   
Avg. wages/employee Rs Th1,264.32,798.8 45.2%   
Avg. net profit/employee Rs Th1,645.84,479.5 36.7%   
INCOME DATA
Net Sales Rs m149,157315,784 47.2%  
Other income Rs m1,1596,232 18.6%   
Total revenues Rs m150,316322,016 46.7%   
Gross profit Rs m34,343100,893 34.0%  
Depreciation Rs m4,27612,648 33.8%   
Interest Rs m6673,998 16.7%   
Profit before tax Rs m30,55890,479 33.8%   
Minority Interest Rs m500-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,59712,116 62.7%   
Profit after tax Rs m23,01278,462 29.3%  
Gross profit margin %23.031.9 72.1%  
Effective tax rate %24.913.4 185.6%   
Net profit margin %15.424.8 62.1%  
BALANCE SHEET DATA
Current assets Rs m92,062329,537 27.9%   
Current liabilities Rs m66,223178,870 37.0%   
Net working cap to sales %17.347.7 36.3%  
Current ratio x1.41.8 75.5%  
Inventory Days Days10679 134.2%  
Debtors Days Days6883 81.3%  
Net fixed assets Rs m62,919204,766 30.7%   
Share capital Rs m5862,399 24.4%   
"Free" reserves Rs m93,133363,997 25.6%   
Net worth Rs m93,719366,397 25.6%   
Long term debt Rs m1,81414,361 12.6%   
Total assets Rs m162,494614,102 26.5%  
Interest coverage x46.823.6 198.0%   
Debt to equity ratio x00 49.4%  
Sales to assets ratio x0.90.5 178.5%   
Return on assets %14.613.4 108.5%  
Return on equity %24.621.4 114.7%  
Return on capital %32.724.8 131.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83844,118 171.9%   
Fx outflow Rs m30,22424,484 123.4%   
Net fx Rs m45,61319,634 232.3%   
CASH FLOW
From Operations Rs m32,78670,822 46.3%  
From Investments Rs m-17,870-42,216 42.3%  
From Financial Activity Rs m-19,153-22,854 83.8%  
Net Cashflow Rs m-4,2396,107 -69.4%  

Share Holding

Indian Promoters % 54.1 63.7 84.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 5.1 155.0%  
FIIs % 27.7 23.0 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 8.3 122.9%  
Shareholders   69,601 133,026 52.3%  
Pledged promoter(s) holding % 8.6 0.5 1,615.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 20, 2018 03:35 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - AJANTA PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS